Merck partners with Zymeworks
Merck & Co. Inc. has licensed worldwide rights to develop new cancer and autoimmune disease drugs using Zymeworks Inc.’s (protein therapeutics development) Azymetric bi-specific antibody production platform.
Drug Discovery Tools
- Large Molecule
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com